Most patients walk into a dermatologist's office hoping to leave with clearer skin or fewer wrinkles. What they rarely consider is the decade-long journey of research, regulatory review, and rigorous testing that made those treatments possible.
Wm. Philip Werschler, MD, has spent more than 30 years working on both sides of that equation, as a board-certified dermatologist treating patients in Spokane, Washington, and as a principal investigator helping to determine which therapies are actually safe and effective enough to reach them.
At both Premier Clinical Research and BreakAway Research, Spokane-based clinical research centers he founded, Dr. Werschler has run as many as several dozen simultaneous clinical trials. That experience has given him a perspective on drug and device development that very few clinicians ever acquire. What he's learned challenges some of the most common assumptions about how medicine gets made.
The Gap Between a Lab Discovery and a Prescription Pad
It's tempting to think of medical breakthroughs as moments, a researcher's eureka followed quickly by a treatment. The reality is far more methodical. In the United States, the FDA's drug approval process typically spans 10 to 15 years from initial compound discovery to patient availability, with clinical trials alone accounting for six to seven of those years. Fewer than 12% of drugs that enter clinical testing ever reach the market.
Dr. Werschler has participated in that process at the investigator level across hundreds of trials. His facility has evaluated treatments for conditions such as:
- Acne
- Warts
- Molluscum
- Fungal infections
- Rosacea
- Skin cancer
- Arthritis
- Motion sickness
- Cosmetic age-related skin changes
- Psoriasis
- Atopic dermatitis
- Hidradenitis
- Urticaria
- Pruritus
- Scleroderma
Each trial requires meticulous documentation, adherence to protocol, and the kind of patient follow-through that only a trusted clinical relationship can sustain.
"The science doesn't happen in a vacuum," he's explained to colleagues. "It happens because patients trust their doctors enough to participate in research that might not benefit them personally but will shape what physicians can offer for decades."
Running Trials at Scale Requires More Than Scientific Knowledge
Managing multiple active trials simultaneously isn't just a logistical feat. It's a systems challenge that demands precision across patient recruitment, protocol compliance, data integrity, and regulatory reporting. Dr. Werschler built Premier Clinical Research to handle that complexity without compromising individual patient care, a balance that is harder to strike than it might appear.
According to the Tufts Center for the Study of Drug Development, the average cost of bringing a new drug to market exceeds $2.6 billion when accounting for failures. A significant portion of that cost comes from trial inefficiencies: poor site selection, slow patient enrollment, and protocol deviations that invalidate data. Research sites that can recruit consistently and maintain data quality are genuinely rare.
Dr. Werschler's site became known as one of those rare facilities, which is why pharmaceutical and device manufacturers repeatedly returned to Premier Clinical Research for studies on novel compounds and technologies. His dual role as practicing dermatologist and principal investigator meant that the patients enrolling in trials were already established in his care, which improved retention rates and reduced the kind of dropout that plagues less integrated research programs.
What Being a Botox Cosmetic FDA Investigator Actually Meant
Dr. Werschler was one of the original FDA investigators for Botox Cosmetic, which received FDA approval for cosmetic use in 2002 and has since become the most performed cosmetic procedure in the United States. Being part of that investigative process wasn't a ceremonial role.
FDA investigators are responsible for:
- Implementing the study protocol at their site.
- Ensuring informed consent is obtained and documented.
- Monitoring patient safety and adverse events.
- Submitting accurate data to the sponsor and ultimately to the FDA.
The agency's approval decisions are built on the aggregate findings from these sites. Investigators who do this work well are directly shaping the evidentiary basis on which a product is judged safe or not safe for millions of future users.
Dr. Werschler's involvement in Botox Cosmetic trials placed him at the center of a treatment category that would ultimately transform aesthetic medicine globally. That early investigative experience informed not just his own practice but his subsequent role as an educator and editor in the field.
How Research and Practice Actually Inform Each Other
One of the things Dr. Werschler has consistently emphasized in his academic writing and presentations is that the relationship between research and clinical practice isn't one-directional. It's not simply that researchers generate findings that practitioners then apply. The best research emerges from clinicians who are deeply embedded in patient care because they know which questions actually matter.
As Editor-in-Chief of Cosmetic Dermatology and the founding aesthetic editor of the Journal of Clinical and Aesthetic Dermatology, a PubMed-listed journal, he has occupied a position that lets him observe what the broader field is studying, what gaps exist in the literature, and which claims being made in the marketplace aren't yet supported by the evidence. That editorial lens reinforces the same evidence-based approach that defines his clinical work.
For patients, this matters in practical terms. A dermatologist who has spent years as a principal investigator reads a study differently than one who hasn't. They:
- Know what the endpoints measured and which outcomes weren't captured.
- Understand why a trial population may not reflect the patients sitting in their exam room.
- Are far less likely to be swayed by marketing that overstates what the data actually supports.
Why Provider Selection Matters More Than Patients Realize
The proliferation of aesthetic medicine has brought with it a wide spectrum of provider qualifications:
- A 2023 analysis published in JAMA Dermatology noted that a growing number of cosmetic procedures are being performed by providers with limited formal training in dermatology or plastic surgery.
- The consequences for patients can range from suboptimal results to serious complications.
Dr. Werschler has addressed this issue in published work and in his role as a founding member and twice past president of the American Society of Cosmetic Dermatology and Aesthetic Surgery. The position of the professional community he helped build is clear. Credentials and training aren't bureaucratic formalities. They're the difference between a provider who understands the pharmacology, anatomy, and adverse event management of a treatment and one who doesn't.
When patients travel 1,500 miles to see a specific physician, as some of Dr. Werschler's patients have, it's a signal that they've done their research and concluded that expertise isn't interchangeable. For treatments that carry real risks and real variability in outcomes, that judgment is well-founded.
What Running Multiple Clinical Trials at Once Teaches About Medicine
Operating at the scale Dr. Werschler has sustained over his career produces insights that aren't available any other way. You learn that the drugs and devices that ultimately succeed aren't always the most impressive in early-phase testing. You learn that study design choices made years before a product reaches patients can quietly shape what it's capable of. And you learn that the regulatory process, frustrating as it can be for developers and patients waiting on approvals, exists because the alternative has historically been worse.
The FDA has approved more than 50 new drugs annually in recent years, each one the product of years of trial work by investigators like Dr. Werschler. The cumulative effect of that research enterprise is a dermatology treatment landscape that's dramatically more capable than it was 30 years ago, with far better safety profiles and far more precisely targeted mechanisms of action.
For Dr. Werschler, that progress isn't an abstraction. It's visible in the outcomes his patients achieve, and in the standard of care he's helped shape through his dual commitment to clinical excellence and evidence-based research. Rather than a measure of capacity alone, his ability to simultaneously perform multiple clinical trials is a reflection of a career built on the conviction that the best care for patients starts with the best possible science.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
